Coronavirus Update: Remedesivir China Trials Halted, Witty To Spearhead WHO's Vaccines Efforts
Ex-GSK Chief To Help Accelerate Development
Plus: Korean firms working on repurposed drug which showed far higher efficacy than remdesivir and chloroquine in pre-clinical tests
You may also be interested in...
Novartis/TScan and Gilead/Kite/oNKo-innate partnerships seek to advance cancer cell therapy. J&J, Bayer among the latest pharmas to unveil partnerships to fight the novel coronavirus.
Gilead’s front-running antiviral to fight the coronavirus has shown rapid improvement in severe patients’ symptoms in one US study but some are not convinced.
Interpretation of remdesivir's compassionate use data is complicated by typical disease course of COVID-19 patients. The uncontrolled data raises hopes for positive trials but is unlikely to change current treatment protocols.